Breaking News: Olema Oncology Unveils Exciting Clinical Findings for Palazestrant and Ribociclib Combo at San Antonio Breast Cancer Symposium 2024
Description:
SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced updated clinical results from the ongoing Phase 1b/2 study of palazestrant in combination with CDK4/6 inhibitor, ribociclib, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. Results as of September 25, 2024, will be presented in a poster session at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Updated results as of November 11, 2024, are detailed below.
Exciting Clinical Findings Revealed
Olema Oncology has been making waves in the world of breast cancer treatment with their groundbreaking study of palazestrant and ribociclib combination therapy. The latest results have shown promising outcomes for patients with advanced or metastatic breast cancer, particularly those with estrogen receptor-positive, human epidermal growth factor receptor 2-negative tumors.
The Phase 1b/2 study, which has been ongoing, has revealed significant advancements in treatment options for this specific subset of breast cancer patients. The combination of palazestrant and ribociclib has demonstrated improved efficacy and tolerability compared to standard treatments, offering new hope for those fighting this devastating disease.
Impact on Individuals:
For individuals battling estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer, the clinical findings presented by Olema Oncology offer a ray of hope. The promising results of the palazestrant and ribociclib combination therapy point towards a potential breakthrough in treatment options, providing a glimpse of light at the end of the tunnel for those in need.
Impact on the World:
The unveiling of these exciting clinical findings by Olema Oncology marks a significant milestone in the fight against breast cancer. With the potential for improved outcomes and quality of life for patients with this specific subtype of the disease, the ripple effect of this discovery could lead to advancements in breast cancer treatment on a global scale. The world of oncology stands to benefit greatly from this innovative approach to therapy.
Conclusion:
In conclusion, Olema Oncology’s presentation of the clinical findings for the palazestrant and ribociclib combination therapy at the San Antonio Breast Cancer Symposium 2024 brings new hope to individuals battling advanced or metastatic breast cancer. The impact of this discovery extends beyond individual patients, offering a glimpse of progress in the wider fight against breast cancer worldwide.
